Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell ...

The world is experiencing a hidden epidemic with kidney disease. More than 850 million people worldwide have some form of ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new clinical and real-world data from its cardiovascular (CV) portfolio presented at the American ...

Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia ® (denosumab), to treat a variety of ...

Chronic Kidney Disease (CKD) has become a growing challenge. A top doctor shared some of its main causes, ways to prevent it ...

Bayer announces finerenone meets primary endpoint in pivotal phase III FIND-CKD study in patients with non-diabetic chronic kidney disease: Berlin Tuesday, March 17, 2026, 15:00 H ...

Detailed price information for Arrivent Biopharma Inc (AVBP-Q) from The Globe and Mail including charting and trades.

Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1Fabhalta ...

A new analysis of hypertension guidelines suggests some older adults — mostly women — with slightly high blood pressure could ...

March marks Kidney Awareness Month, a crucial time to address the rising prevalence of kidney disease in South Africa, affecting 6% to 10% of the population.

Zongertinib provided substantial clinical benefit for patients with advanced or metastatic HER2-mutant advanced non-small cell lung cancer, surpassing the historical standard of care efficacy for this ...